SG11201913236QA - 5-membered and bicyclic heterocyclic amides as inhibitors of rock - Google Patents

5-membered and bicyclic heterocyclic amides as inhibitors of rock

Info

Publication number
SG11201913236QA
SG11201913236QA SG11201913236QA SG11201913236QA SG11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA
Authority
SG
Singapore
Prior art keywords
membered
rock
inhibitors
bicyclic heterocyclic
heterocyclic amides
Prior art date
Application number
SG11201913236QA
Inventor
Peter W Glunz
Vladimir Ladziata
Lucca Indawati De
George O Tora
Tarun Kumar Maishal
Raghuram Tangirala
Kamalraj Thiyagarajan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201913236QA publication Critical patent/SG11201913236QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201913236QA 2017-07-12 2018-07-11 5-membered and bicyclic heterocyclic amides as inhibitors of rock SG11201913236QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531563P 2017-07-12 2017-07-12
PCT/US2018/041573 WO2019014308A1 (en) 2017-07-12 2018-07-11 5-membered and bicyclic heterocyclic amides as inhibitors of rock

Publications (1)

Publication Number Publication Date
SG11201913236QA true SG11201913236QA (en) 2020-01-30

Family

ID=63036489

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201913236QA SG11201913236QA (en) 2017-07-12 2018-07-11 5-membered and bicyclic heterocyclic amides as inhibitors of rock

Country Status (19)

Country Link
US (2) US11078197B2 (en)
EP (1) EP3652168B1 (en)
JP (1) JP7206252B2 (en)
KR (1) KR20200028423A (en)
CN (1) CN110869363B (en)
AR (1) AR112273A1 (en)
AU (1) AU2018300094A1 (en)
BR (1) BR112020000284A2 (en)
CA (1) CA3069311A1 (en)
CL (1) CL2019003747A1 (en)
CO (1) CO2019014455A2 (en)
EA (1) EA202090256A1 (en)
ES (1) ES2882432T3 (en)
IL (1) IL271905B (en)
PE (1) PE20200388A1 (en)
SG (1) SG11201913236QA (en)
TW (1) TW201908293A (en)
WO (1) WO2019014308A1 (en)
ZA (1) ZA202000877B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102491994B1 (en) 2016-07-07 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 Spirolactam as an inhibitor of ROCK
WO2018102325A1 (en) 2016-11-30 2018-06-07 Bristol-Myers Squibb Company Tricyclic rho kinase inhibitors
TW201908293A (en) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine
US11306081B2 (en) 2017-07-12 2022-04-19 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
ES2894128T3 (en) 2017-07-12 2022-02-11 Bristol Myers Squibb Co ROCK 5,6- or 6,6-membered bicyclic aminoheterocyclic and 5-membered aminoheterocyclic inhibitors for the treatment of heart failure
US11447487B2 (en) 2017-07-12 2022-09-20 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
ES2937039T3 (en) 2017-11-03 2023-03-23 Bristol Myers Squibb Co ROCK Diazaspiro Inhibitors
JP2021526123A (en) * 2018-05-29 2021-09-30 シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー. Autotaxin inhibitors and their use
US10711000B2 (en) 2018-05-29 2020-07-14 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
MX2021005273A (en) 2018-11-06 2021-09-08 Cervello Therapeutics LLC Rock kinase inhibitors.
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
CA3226468A1 (en) 2021-08-02 2023-02-09 Andrew Edmunds Microbiocidal pyrazole derivatives
WO2023129512A1 (en) * 2021-12-31 2023-07-06 President And Fellows Of Harvard College Bicyclic inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof
WO2024013736A1 (en) * 2022-07-12 2024-01-18 Adama Makhteshim Ltd. Process for preparing substituted benzamides
US20240092755A1 (en) * 2022-08-16 2024-03-21 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227480B2 (en) 2006-06-08 2012-07-24 Ube Industries, Ltd. Indazole derivative having spiro ring structure in side chain
ES2729424T3 (en) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Rho kinase inhibitors
CL2007003874A1 (en) 2007-01-03 2008-05-16 Boehringer Ingelheim Int COMPOUNDS DERIVED FROM BENZAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CARDIOVASCULAR DISEASES, HYPERTENSION, ATEROSCLEROSIS, RESTENOSIS, ICTUS, HEART FAILURE, ISCHEMICAL INJURY, HYPERTENSION
CA2737738A1 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
ES2684776T3 (en) 2013-01-18 2018-10-04 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as ROCK inhibitors
CN105102448B (en) 2013-02-28 2018-03-06 百时美施贵宝公司 Phenylpyrazole derivatives as ROCK1 and ROCK2 inhibitor
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
TW201506024A (en) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 Tricyclic carboxamide derivatives as potent ROCK inhibitors
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
JP6779214B2 (en) 2015-01-09 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cyclic urea as a ROCK inhibitor
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
AR107354A1 (en) 2016-01-13 2018-04-18 Bristol Myers Squibb Co SPIROHEPTAN SALICILAMIDS AND RELATED COMPOUNDS AS ROCK INHIBITORS
CN109153663B (en) 2016-05-27 2021-08-13 百时美施贵宝公司 Triazolones and tetrazolones as ROCK inhibitors
KR102491994B1 (en) 2016-07-07 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 Spirolactam as an inhibitor of ROCK
EP3481828B1 (en) 2016-07-07 2020-09-16 Bristol-Myers Squibb Company Spiro-fused cyclic ureas as inhibitors of rock
CN110049977B (en) 2016-07-07 2022-01-18 百时美施贵宝公司 Lactam, cyclic urea and carbamate and triazolone derivatives as potent and selective ROCK inhibitors
WO2018102325A1 (en) 2016-11-30 2018-06-07 Bristol-Myers Squibb Company Tricyclic rho kinase inhibitors
TW201908293A (en) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine
ES2894128T3 (en) 2017-07-12 2022-02-11 Bristol Myers Squibb Co ROCK 5,6- or 6,6-membered bicyclic aminoheterocyclic and 5-membered aminoheterocyclic inhibitors for the treatment of heart failure
US11306081B2 (en) 2017-07-12 2022-04-19 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
US11447487B2 (en) 2017-07-12 2022-09-20 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
ES2937039T3 (en) 2017-11-03 2023-03-23 Bristol Myers Squibb Co ROCK Diazaspiro Inhibitors

Also Published As

Publication number Publication date
EA202090256A1 (en) 2020-05-22
US11078197B2 (en) 2021-08-03
CN110869363B (en) 2024-01-05
TW201908293A (en) 2019-03-01
IL271905A (en) 2020-02-27
EP3652168B1 (en) 2021-06-30
WO2019014308A1 (en) 2019-01-17
AU2018300094A1 (en) 2020-02-27
ZA202000877B (en) 2021-08-25
US20210147406A1 (en) 2021-05-20
IL271905B (en) 2022-08-01
CA3069311A1 (en) 2019-01-17
ES2882432T3 (en) 2021-12-01
US11673886B2 (en) 2023-06-13
JP2020526556A (en) 2020-08-31
CO2019014455A2 (en) 2020-01-17
CL2019003747A1 (en) 2020-05-15
BR112020000284A2 (en) 2020-07-14
EP3652168A1 (en) 2020-05-20
PE20200388A1 (en) 2020-02-24
KR20200028423A (en) 2020-03-16
US20220356179A1 (en) 2022-11-10
AR112273A1 (en) 2019-10-09
JP7206252B2 (en) 2023-01-17
CN110869363A (en) 2020-03-06

Similar Documents

Publication Publication Date Title
ZA202000877B (en) 5-membered and bicyclic heterocyclic amides as inhibitors of rock
IL267090A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
SG11202010822SA (en) Substituted heterocyclic inhibitors of ptpn11
HK1259232A1 (en) Substituted inhibitors of menin-mll and methods of use
EP3463343A4 (en) Heterocyclic inhibitors of ptpn11
IL260448B (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
IL270844A (en) Novel inhibitors of map4k1
IL279949A (en) Heterocyclic inhibitors of mct4
IL271109A (en) Imidazole-containing inhibitors of alk2 kinase
EP3609882A4 (en) Heterocyclic inhibitors of pcsk9
IL274504A (en) Acss2 inhibitors and methods of use thereof
IL254430A0 (en) Heterocyclic compounds useful as inhibitors of tnf
HK1248684A1 (en) Usp7 inhibitor compounds and methods of use
PT3458448T (en) Methods of using fasn inhibitors
HK1231484A1 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 tnks1 / tnks2
IL273974A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
IL272190A (en) Inhibitors of ror gamma
EP3697419A4 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
GB201709136D0 (en) New therapeutic uses of enzyme inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
PL3362450T3 (en) N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis
HK1251560A1 (en) Crystals of thiadiazole derivative dpp-iv inhibitors and uses thereof
AU2017900935A0 (en) Heterocyclic inhibitors of PCSK9